Who are Vyvgart's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Blenrep, RYSTIGGO, Wydase, Efgartigimod, Trastuzumab and Hyaluronidase-oysk, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/efgartigimod-alfa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Vyvgart — Competitive Intelligence Brief

Vyvgart (EFGARTIGIMOD ALFA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Endoglycosidase [EPC]. Area: Immunology.

marketed Endoglycosidase [EPC] IgG receptor FcRn large subunit p51 Immunology Recombinant protein Live · refreshed every 30 min

Target snapshot

Vyvgart (EFGARTIGIMOD ALFA) — Argenx Bv. Vyvgart works by binding to the p51 subunit of the FcRn receptor, preventing it from recycling antibodies back into the bloodstream.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vyvgart TARGET	EFGARTIGIMOD ALFA	Argenx Bv	marketed	Endoglycosidase [EPC]	IgG receptor FcRn large subunit p51	2021-01-01
Blenrep	Blenrep	Duke University	marketed		Low affinity immunoglobulin gamma Fc region receptor III-A, High affinity immunoglobulin gamma Fc receptor I, IgG receptor FcRn large subunit p51
RYSTIGGO	ROZANOLIXIZUMAB-NOLI	UCB INC	marketed	Neonatal Fc Receptor Blocker [EPC]	IgG receptor FcRn large subunit p51
Wydase	HYALURONIDASE	Baxter	marketed	Endoglycosidase	hyaluronic acid	1950-01-01
Efgartigimod	Efgartigimod	M. Peter Marinkovich	marketed	Endoglycosidase [EPC]	FcRn
Trastuzumab and Hyaluronidase-oysk	Trastuzumab and Hyaluronidase-oysk	Adrienne G. Waks	marketed	Endoglycosidase [EPC]	HER2
Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf	Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf	Genentech, Inc.	marketed	Endoglycosidase [EPC]

Recent regulatory actions (last 90 days)

2026-02-13 — Wydase · FDA · approved · US · Baxter

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Endoglycosidase [EPC] class)

Adrienne G. Waks · 1 drug in this class
Argenx Bv · 1 drug in this class
Genentech, Inc. · 1 drug in this class
M. Peter Marinkovich · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vyvgart — Competitive Intelligence Brief. https://druglandscape.com/ci/efgartigimod-alfa. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab